0001641172-25-014700.txt : 20250611 0001641172-25-014700.hdr.sgml : 20250611 20250611160524 ACCESSION NUMBER: 0001641172-25-014700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250610 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250611 DATE AS OF CHANGE: 20250611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40023 FILM NUMBER: 251039943 BUSINESS ADDRESS: STREET 1: 505 MONTGOMERY STREET STREET 2: 10TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 505 MONTGOMERY STREET STREET 2: 10TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-K 1 form8-k.htm 8-K
false 0000109657 0000109657 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report:

(Date of earliest event reported)

 

June 10, 2025

 

 

 

GT Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other Jurisdiction

of Incorporation)

 

1-40023

(Commission

File Number)

  

94-1620407

(IRS Employer

Identification No.)

 

N/A1

(Address of Principal Executive Offices and zip code)

 

(415)-919-4040

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Series   Trading Symbol(s)   Name of each Exchange on which registered
Common stock, $0.001 par value   GTBP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

1Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company’s principal executive offices may be directed to 505 Montgomery Street, 10th Floor, San Francisco, California 94111, or by email to auditcommittee@gtbiopharma.com.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Common Shares Purchase Agreement

 

As previously disclosed on May 14, 2025, GT Biopharma, Inc. (the “Company”) entered into a common shares purchase agreement (the “Purchase Agreement”) with investors (each an “Investor,” and collectively, the “Investors”) relating to a committed equity facility (the “Facility”). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $20 million of its common stock subject to certain conditions and limitations set forth in the Purchase Agreement. Pursuant to the Purchase Agreement, the issuance of shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company, to each Investor is subject to a beneficial ownership limitation of 4.99% (the “Beneficial Ownership Limitation”), which in ease case restricts each Investor from purchasing shares of Common Stock under the Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by such Investor and its affiliates, would result in the beneficial ownership by the Investor and its affiliates (on an aggregated basis) of more than 4.99% of the outstanding voting power or number of shares of Common Stock.

 

On June 10, 2025, the Company and the Investors entered into the First Amendment to Common Shares Purchase Agreement (the “First Amendment to Common Shares Purchase Agreement”) to increase the Beneficial Ownership Limitation to permit an Investor to beneficially own up to 9.99% of the outstanding voting power or number of shares of Common Stock under the Purchase Agreement.

 

The foregoing description of the First Amendment to Common Shares Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such exhibit, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.

 

On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.

 

On June 10, 2025, the Board ratified the appointment of Mr. Mun-Gavin to the Audit Committee of the Board, the Compensation Committee of the Board (the “Compensation Committee) and the Nominating and Corporate Governance Committee of the Board, with Mr. Mun-Gavin serving as chair of the Compensation Committee, effective as of the date he commenced service on the Board, having determined that Mr. Mun-Gavin qualifies as “independent” in accordance with Nasdaq’s listing requirements, including those requirements specifically applicable to audit committee members.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

No.

   Description
10.1   First Amendment to Common Shares Purchase Agreement, dated as of June 10, 2025, between the Company and the investors identified therein.
104   Cover Page Interactive Date File (embedded within the Inline XRBL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GT BIOPHARMA, INC.
     
Date: June 11, 2025 By: /s/ Alan Urban
    Alan Urban
    Chief Financial Officer

 

 

 

 EX-10.1 2 ex10-1.htm EX-10.1

 

Exhibit 10.1

 

FIRST AMENDMENT TO COMMON SHARES PURCHASE AGREEMENT

 

THIS FIRST AMENDMENT TO COMMON SHARES PURCHASE AGREEMENT (this “Amendment”), dated as of June 10, 2025, by and between Five Narrow Lane, L.P., a Delaware limited partnership And/or its assignee and Bristol Capital, LLC, a Delaware limited liability company and/or its assignee (each an “Investor” and together, the “Investors”), and GT Biopharma, Inc. a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Purchase Agreement (as defined below).

 

RECITALS

 

A. The Company and the Investors are parties to that certain Common Shares Purchase Agreement, dated as of May 14, 2025 (the “Purchase Agreement”).

 

B. Pursuant to Section 10.6 of the Purchase Agreement, the Purchase Agreement may be amended upon the written consent by the Company and the Investors.

 

NOW, THEREFORE, in consideration of the agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

AMENDMENTS

 

1.Amendment. Section 3.4 of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:

 

Section 3.4. Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, (i) Five Narrow Lane, L.P. shall not be obligated to purchase or acquire, and shall not purchase or acquire, any Common Shares under this Agreement which, when aggregated with all other Common Shares then beneficially owned by Five Narrow Lane, L.P. and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by Five Narrow Lane, L.P. and its affiliates (on an aggregated basis) of more than 4.99% of the outstanding voting power or number of Common Shares, and (ii) Bristol Capital, LLC shall not be obligated to purchase or acquire, and shall not purchase or acquire, any Common Shares under this Agreement which, when aggregated with all other Common Shares then beneficially owned by Bristol Capital, LLC and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by Bristol Capital, LLC and its affiliates (on an aggregated basis) of more than 9.99% of the outstanding voting power or number of Common Shares (collectively, the “Beneficial Ownership Limitation”). Upon the written request of an Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent is open for business) confirm orally or in writing to the Investor the number of Common Shares then outstanding. The Investors and the Company shall each cooperate in good faith in the determinations required under this Section 3.4 and the application of this Section 3.4. The Investor’s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.

 

2.Securities Laws Disclosure. The Company shall, by not later than 8:30 a.m. (local time in New York, New York) on June 11, 2025, file a Current Report on Form 8-K, disclosing the terms of this Amendment, and including a copy of this Amendment (or the form thereof) as an exhibit thereto, with the Commission.

 

 

 

 

3.Effect of Amendment. Except as specifically amended herein, all terms of the Purchase Agreement shall remain in full force and effect and are hereby ratified and affirmed. In the event and to the extent of any conflict between the terms of the Purchase Agreement and this Amendment, this Amendment shall control. The Purchase Agreement may not be further amended or modified except as set forth in the Purchase Agreement. Each reference in the Purchase Agreement to the Purchase Agreement shall mean the Purchase Agreement as amended hereby.

 

4.Counterparts/Telecopy. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. Delivery of executed counterparts of this Amendment by telecopy or other secure electronic format (.pdf) shall be effective as an original.

 

5.Entire Agreement, Amendment and Waiver. This Amendment, together with the Purchase Agreement and the Transaction Documents, constitute the entire agreement of the parties hereto and thereto relating to the subject matter hereof and thereof and supersede all prior and contemporaneous contracts or agreements with respect thereto, whether oral or written. This Amendment may not be amended, modified or supplemented and no waivers of consents to or departures from the provisions hereof may be given except pursuant to a writing signed by all of the parties hereto.

 

6.Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their successors and permitted assigns.

 

7.Headings. The headings of the sections hereof are provided for convenience only and shall not in any way affect the meaning or construction of any provision of this Amendment.

 

8.Severability. If any provision of this Amendment is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Amendment shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

9.Further Assurances. The parties shall execute and deliver such additional documents and instruments and perform such additional acts as may be necessary or appropriate to effectuate, carry out, and perform all of the terms, provisions, and conditions of this Amendment and the transactions contemplated hereby

 

[signature pages follow]

 

 

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

  COMPANY:
   
  GT Biopharma, Inc.
   
  By: /s/ Michael Breen
  Name: Michael Breen
  Its: Executive Chairman and Chief Executive Officer

 

[Signature Page to Amendment No. 1 to Purchase Agreement]

 

 

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

  PURCHASERS:
     
  FIVE NARROW LANE, L.P.
     
  By: /s/ Arie Rabinowitz
  Name: Arie Rabinowitz
  Its: Partner

 

[Signature Page to Amendment No. 1 to Purchase Agreement]

 

 

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly executed and delivered as of the date first above written.

 

PURCHASERS:  
     
BRISTOL CAPITAL LLC  
   
By: /s/ Paul Kessler  
Name: Paul Kessler  
Its: Principal  

 

[Signature Page to Amendment No. 1 to Purchase Agreement]

 

 

 

 

 

 EX-101.SCH 3 gtbp-20250610.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gtbp-20250610_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 gtbp-20250610_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover
Jun. 10, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 10, 2025
Entity File Number 1-40023
Entity Registrant Name GT Biopharma, Inc.
Entity Central Index Key 0000109657
Entity Tax Identification Number 94-1620407
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 505 Montgomery Street
Entity Address, Address Line Two 10th Floor
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94111
City Area Code (415)
Local Phone Number 919-4040
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol GTBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gtbiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm gtbp-20250610.xsd gtbp-20250610_lab.xml gtbp-20250610_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GTBP", "nsuri": "http://gtbiopharma.com/20250610", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "gtbp-20250610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "gtbp-20250610_lab.xml" ] }, "presentationLink": { "local": [ "gtbp-20250610_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://gtbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-06-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-06-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001641172-25-014700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641172-25-014700-xbrl.zip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end XML 15 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000109657 2025-06-10 2025-06-10 iso4217:USD shares iso4217:USD shares false 0000109657 8-K 2025-06-10 GT Biopharma, Inc. DE 1-40023 94-1620407 (415) 919-4040 false false false false Common stock, $0.001 par value GTBP NASDAQ false 505 Montgomery Street 10th Floor San Francisco CA 94111